University of Mississippi

eGrove
Honors Theses

Honors College (Sally McDonnell Barksdale
Honors College)

Spring 5-1-2021

Emotion regulation among adults with asthma: Links with shortacting inhaler medication overuse and utilization of acute medical
care
Victoria A. Green
University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/hon_thesis
Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Psychiatry and Psychology
Commons

Recommended Citation
Green, Victoria A., "Emotion regulation among adults with asthma: Links with short-acting inhaler
medication overuse and utilization of acute medical care" (2021). Honors Theses. 1587.
https://egrove.olemiss.edu/hon_thesis/1587

This Undergraduate Thesis is brought to you for free and open access by the Honors College (Sally McDonnell
Barksdale Honors College) at eGrove. It has been accepted for inclusion in Honors Theses by an authorized
administrator of eGrove. For more information, please contact egrove@olemiss.edu.

EMOTION REGULATION AMONG ADULTS WITH ASTHMA: LINKS WITH SHORTACTING INHALER MEDICATION OVERUSE AND UTILIZATION OF ACUTE MEDICAL
CARE

by
Victoria A. Green

A thesis submitted to the faculty of The University of Mississippi in partial fulfillment of the
requirements of the Sally McDonnell Barksdale Honors College.

Oxford
May 2021

Approved by
_____________________________
Advisor: Dr. Aaron Lee
_____________________________
Reader: Dr. Sujith Ramachandran
_____________________________
Reader: Dr. Laura Dixon

© 2020
Victoria A. Green
ALL RIGHTS RESERVED

ii

ACKNOWLEDGEMENTS
First and foremost, I would like to thank my thesis advisor, Dr. Aaron Lee, for being so
patient and guiding me throughout this process of forming and writing a thesis. I am Dr. Lee’s
first honors student and I can honestly say that he has been the best thesis advisor ever! Dr. Lee
has always been open to helping me and continues to motivate me whenever I have any doubts
or uncertainties. I am forever thankful to have encountered him during my time here at the
University of Mississippi.
Second, I would like to thank Patric Leukel, a graduate student from Dr. Lee’s lab, for
helping me if I had any questions and working with me on learning to use the software for this
research. I am also very thankful for Dr. Sujith Ramachandran from the School of Pharmacy and
Dr. Laura Dixon from the Department of Psychology for their time and willingness to serve as
readers of my thesis.
Next, I would like to thank the Sally McDonnell Barksdale Honors College for serving as
my “home away from home” for the past four years. The Honors College faculty and staff, along
with my family, have been so supportive throughout my college experience.
Last but not least, I would like to express my appreciation to my friends and classmates.
We’ve laughed together, cried together, motivated one another, had several sleepless nights
together, and most importantly, made memories together.
Everyone mentioned has helped me to successfully write this thesis, something I once
thought I was incapable of doing. To the University of Mississippi, thank you for every memory
I’ve made since I stepped foot on this campus. I am forever grateful and I will always be a rebel.
I cannot wait to represent the University well when I finally accomplish my goal of becoming a
top-notch pharmacist. Hotty Toddy!

iii

ABSTRACT
VICTORIA A. GREEN: Emotion regulation among adults with asthma: Links with short-acting
inhaler medication overuse and utilization of acute medical care
(Under the direction of Dr. Aaron Lee)
Effective control of asthma symptoms requires daily self-management activities,
including use of short-acting or “rescue” inhaled medications. Overuse of short-acting inhaled
medications, such as albuterol, can have negative side-effects, including respiratory infections
and worse asthma symptom control. Existing research suggests that emotion plays an important
role in airway inflammation and asthma symptom control. The objective of this study was to
determine whether difficulties regulating emotion was associated with overuse of short-acting
inhaled medications and acute medical care usage in adults with asthma. The sample included
401 adults with asthma recruited from an online panel of adults with chronic respiratory disease.
Respondents completed a survey that included measures of short-acting medication use, acute
medical service use, and emotion regulation (Difficulties in Emotion Regulation Scale [DERS]).
Sequential binary logistic regression models were used to examine the association between
DERS scores with two indicators of short-acting inhaled medication overuse: using >3 canisters
of short-acting inhaled medications in the past three months or self-reported overuse (i.e., using
short-acting inhaled medications more than prescribed) while controlling for patient
characteristics (current smoking and health insurance status) and comorbid mental health
conditions (probable depression and probable anxiety). The results showed that greater
difficulties in emotion regulation was significantly associated with greater odds of using more
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than three canisters in the past three months (AOR = 1.023, 95%CI [1.012, 1.035], p < .001) and
using short-acting inhaled medications more than prescribed (AOR = 1.024, 95%CI [1.014,
1.035], p < .001) as well as with greater odds of emergency department visits (AOR = 1.018,
95%CI [1.009, 1.028], p <.001), and hospitalizations (AOR = 1.017, 95%CI [1.007, 1.028],
p=.001) in the prior 12-months – even after adjusting for probable depression and probable
anxiety, current smoking, and health insurance status. In conclusion, emotion dysregulation may
play an important role in overuse of short-acting inhaled medications and acute medical care
utilization among adults with asthma. Evidence-based interventions to reduce difficulties in
emotion regulation may help improve problematic patterns of short-acting medication overuse
among adults with asthma.
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INTRODUCTION
Asthma is a chronic respiratory disease with major public health impacts (National Heart
Lung and Blood Institute, 2007). The prevalence of asthma in the United States is increasing
(Centers for Disease Control and Prevention, 2011). Approximately 50 percent of adults with
current asthma have poorly controlled asthma symptoms (Centers for Disease Control and
Prevention, 2014). Poor asthma symptom control is associated with increased risk of permanent
changes in respiratory severity (Gosavi, Nadig, & Haran, 2016), greater functional limitations
(e.g., greater asthma symptom burden; Everhart, Smyth, Santuzzi, & Fiese, 2010), lower quality
of life (Hossny, Caraballo, Casale, El-Gamal, & Rosenwasser, 2017), and greater disability (Le
& Simon, 2006). Additionally, adults with poorly controlled asthma symptoms have higher use
of acute medical care services (e.g., emergency department visits and hospitilizations; Braido,
2013) compared to those with adequate symptom control. Use of these acute healthcare services
account for the largest proportion of health care costs among adults with asthma (Bahadori et al.,
2009; Ivanova et al., 2012; Rabe et al., 2004). Overall, these results highlight the importance of
asthma symptom control.
Effective control of asthma symptoms requires routine self-management activities,
including use of short-acting or “rescue” inhaler medications (National Heart & Institute, 2007;
Pinnock et al., 2017). However, overuse of short-acting inhaled medications, such as albuterol,
can have negative side-effects (Taylor, 2009). For example, overuse of short-acting inhaled
medications is associated with more severe asthma symptoms (O'Byrne, 2004). Patients with
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asthma who overuse short-acting inhaled medications may experience more frequent symptom
exacerbations, which are characterized by a progressive increase in dyspnea and respiratory
symptoms (e.g., cough, wheezing or chest tightness) and by a decrease in pulmonary function
(Rodrigo, Rodrigo, & Hall, 2004). Greater frequency of acute exacerbations is associated with
long-term decline in lung functioning and increased risk of early mortality (Donaldson,
Seemungal, Bhowmik, & Wedzicha, 2002; Matsunaga et al., 2014; Rennard & Farmer, 2004;
Santibanez et al., 2016; Schmidt et al., 2014). Over time, more frequent acute symptom
exacerbations may contribute to irreversible airway remodeling and permanent loss of functional
respiratory capacity (Rennard & Farmer, 2004). A retrospective analysis using data from the
Medical Expenditure Panel Study found that overuse of short-acting beta agonists was associated
with worse mental and physical health (Hee Hong, Sanders, & West, 2006; Slejko et al., 2014).
Finally, overuse of short-acting inhaled medications has been shown to be associated with
coexisting medical conditions (e.g., chronic bronchitis and emphysema; Diette et al., 1999) and
greater risk of developing metabolic syndromes, such as prediabetes and type 2 diabetes
(Serafino-Agrusa, Spatafora, & Scichilone, 2015).
Overuse of short-acting inhaled medications is also linked with higher rates of costly
acute healthcare use, such as emergency department visits and hospitalizations (Anis et al.,
2001). In the United States of America, approximately 400,000 asthma patients were
hospitalized in 2010 and hospital inpatient stays totaled roughly 200,000 in 2016 (Centers for
Disease Control and Prevention, 2017, 2020). Individuals with asthma also accounted for
approximately 1.7 million asthma-related emergency department visits in the United States in
2016 (Centers for Disease Control and Prevention, 2020). High rates of emergency department
visits and hospitalizations among individuals with asthma result in major economic burden
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(Bahadori et al., 2009). For example, in the United States, the average cost of emergency
department visits and hospitalizations for adults with asthma per visit is approximately $1500
and $3100, respectively (Wang, Srebotnjak, Brownell, & Hsia, 2014). Prior studies show that
emergency department visits alone, due to worsening of asthma symptoms or poor medication
adherence, make up a third of total asthma costs in the United States (Hamdan et al., 2012).
Asthma related emergency department visits and hospitalizations also increase an individual’s
risk of developing several nosocomial infections via contact with ill people and disease-causing
pathogens (Monegro & Regunath, 2018). Together, these results underscore the substantial costs
and medical complications associated with emergency department visits and hospitalizations.
Adults with asthma and comorbid depressive and anxiety disorders have poorer symptom
control and more frequent use of acute services compared to adults without comorbid anxiety
and depression (Baiardini, Sicuro, Balbi, Canonica, & Braido, 2015; Di Marco et al., 2010;
Katon, Lin, & Kroenke, 2007; Kullowatz, Kanniess, Dahme, Magnussen, & Ritz, 2007).
Moreover, evidence suggests that adults with asthma and comorbid depression and anxiety are
more likely to overuse short-acting inhaled medications (Gerald, Carr, Wei, Holbrook, & Gerald,
2015; Kullowatz et al., 2007). Some authors have suggested that overuse of short-acting inhaled
mediations (e.g., beta 2 agonists) may be a marker for psychological distress among patients with
asthma (Gerald et al., 2015). Mental health conditions, such as depression and anxiety, share
common underlying transdiagnostic vulnerabilities (Krueger & Eaton, 2015). Among patients
with asthma, these vulnerabilities may contribute to the expression of mental health symptoms
and maladaptive patterns of short-acting medication use. In addition to overuse of short-acting
inhaled medications, psychiatric comorbidities have also been linked to greater use of acute
medical care among individuals with asthma and other chronic respiratory diseases (Di Marco et
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al., 2010; Leigh, 2019). In particular, anxiety and depression are associated with increased
hospitalizations in adults in asthma, with depression playing a more significant role (Kullowatz
et al., 2007). Similar studies indicate that among adults with asthma and depression, the
likelihood of utilizing emergency department visits or acute medical care services is doubled
when compared to those without depression (Patel, Patel, & Baptist, 2017). Overall, this
evidence suggests that psychological distress may play an important role in the frequently
observed association between mental health comorbidities and acute medical care use among
adults with asthma.
Emotion Regulation is the modulating and processing of emotional experiences that is
necessary to manage and understand the emotional stressors common in patients with chronic
illnesses (Gratz & Roemer, 2004; Wierenga, Lehto, & Given, 2017). Patients who have
difficulties with emotion regulation are less able to modulate strong emotional experiences and
may have greater difficulty coping with adversities, hardships or daily life stressors. Importantly,
dysregulation of emotions is common among patients with mental problems such as depression
and anxiety (Amstadter, 2008; Bender, Reinholdt-Dunne, Esbjørn, & Pons, 2012; Mennin,
Holaway, Fresco, Moore, & Heimberg, 2007). Emotion and difficulties regulating emotional
experiences may also play an important role in symptom severity and respiratory function,
among patients with asthma. For example, studies show that among adults with asthma,
experimentally induced positive affect leads to greater inability to detect respiratory symptoms,
whereas experimentally induced negative affect leads to over-perception of respiratory
symptoms (Ghorbani, Khosravani, Ardakani, Alvani, & Akbari, 2017). In addition,
experimentally induced negative emotions have been shown to precipitate physiological changes
in respiration among patients with asthma, including airway inflammation and reduced forced
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expiratory volume (Isenberg, Lehrer, & Hochron, 1992; Kullowatz et al., 2008; Levenson, 1979;
Ritz & Kullowatz, 2005; Ritz & Steptoe, 2000; Ritz, Steptoe, DeWilde, & Costa, 2000;
Rosenkranz et al., 2005; Von Leupoldt & Dahme, 2005). Some evidence suggests that
individuals with chronic respiratory diseases, such as asthma, have more difficulty recognizing
and controlling their emotions compared to adults without asthma (Janssens, Verleden, De
Peuter, Van Diest, & Van den Bergh, 2009). Importantly, among young adults with asthma,
negative affectivity predicts greater deliberate medication non-adherence and poorer respiratory
function (Axelsson, 2013). Yet, no studies to date have examined whether difficulties with
regulating emotion are linked with overuse of short-acting inhaled medications or with increased
use of acute medical care services among adults with asthma.
Accordingly, the purpose of this study was to examine the associations of emotion
regulation with short-acting inhaled medications and acute medical care use among adults with
asthma. We hypothesized that greater difficulties in emotion regulation would be associated with
greater short-acting inhaled medication overuse and with greater use of acute medical care (e.g.,
emergency department visits and hospitalizations) above and beyond probable depression and
anxiety, and patient factors associated with worse asthma symptom severity and health care
utilization (i.e., smoking, health insurance status).
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METHODS
Participants
We recruited and surveyed members of a web-based panel of adults with chronic
respiratory diseases, including asthma and COPD (i.e., chronic bronchitis, emphysema). To be
included in this study, panel members had to 1) be 18 years of age or older, 2) report having
current asthma, and 3) report using a short-acting or “rescue” inhaler during the prior three
months. A total of 851 panel members initiated the survey. Of these panel members, 778 (91.4%)
provided informed consent to participate in the study. Among those who provided informed
consent, 428 (55.0%) indicated that they had been diagnosed with asthma by a health care
professional. Of those who reported a prior diagnosis of asthma, 27 (6.3%) reported that they did
not currently have asthma and were not included in this study. Thus, the total sample included
401 adults with asthma. A subsample of 326 (81.3%) respondents indicated that they had used a
short-acting or “rescue” inhaler in the past 3 months.
Dependent Variables
Overuse of Short-Acting Inhaled Medications. We assessed short-acting inhaler use
using two separate items. First, respondents were asked whether they had used more than three
canisters of short-acting inhaled medications (e.g., albuterol) in the past three months (Have you
used more than three canisters of quick-relief or “rescue inhalers” in the past 3 months?). Those
who reported using more than three canisters in the last three months were categorized as
overusing short-acting inhaled medications. This definition of inhaler medication overuse is
based on findings from previous studies showing that patients using three or more canisters of
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short-acting or “rescue” inhaler medication, during a prior three-month period, have three times
greater risk of asthma-related emergency department visits and hospitalizations (Silver et al.,
2010), greater symptom burden, lower symptom control and poorer quality of life (Gerald et al.,
2015). Second, respondents were asked to rate the extent to which they used short-acting inhaled
medications more than prescribed by their health care provider (During the last three months,
have you ever used your short acting or rescue inhaler more than your doctor prescribed
because you felt that your symptoms were getting worse?) on a Likert scale from 1 (None of the
time), 2 (A little of the time), 3 (Some of the time), 4 (Most of the time), to 5 (All of the time).
Respondents who endorsed using their short-acting inhaler medications “Most of the time” or
“All of the time” were categorized as over-users. This single face-valid item was used to
corroborate self-reported short-acting inhaler overuse as determined using respondents’ reported
use of more than three canisters of inhaler medications in the prior three-month period.
Use of Acute Medical Care. Two types of acute medical care usage were assessed in
this study: emergency department visits and hospitalizations. We measured emergency
department visits by asking respondents if they had visited the emergency room in the past
twelve months (Have you had to visit an emergency room in the past 12 months because of your
respiratory condition?). Similarly, respondents were asked whether they had to be admitted to
the hospital in the past twelve months (Have you had to be admitted to the hospital in the past 12
months because of your respiratory condition?). Responses to both items were coded as “No” =
0, or “Yes” = 1.
Predictor Variables
Patient Characteristics. A single item from the Medical Expenditure Panel survey was
used to determine whether or not a participant currently smokes cigarettes (Do you now smoke
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cigarettes, every day, some days, or not at all?). A separate item was used to determine the
health insurance status of each participant (Have you had health insurance during the past 12months?).
Probable Depression. The Patient Health Questionnaire-2 (PHQ-2) is a two-item
measure commonly used to screen for signs of depression. Respondents indicated the frequency,
over the last two weeks, with which they have experienced “little interest or pleasure in doing
things,” and “feeling down, depressed or hopeless,” on a four-point Likert scale from 0 (not at
all) to 3 (nearly every day). Responses were summed and a respondent with a total score of three
or greater was categorized as having probable depressive symptoms. In previous studies, a cutpoint of three or greater on the PHQ-2 has demonstrated up to 97 percent sensitivity and 67
percent specificity among adults (Whooley, Avins, Miranda, & Browner, 1997).
Probable Anxiety. The Generalized Anxiety Disorder-2 (GAD-2) was used to determine
whether respondents had a probable anxiety disorder. The GAD-2 is two-item measure that is
commonly used in primary care clinics to screen for patients with anxiety disorders. Respondents
indicated the frequency with which they have been “nervous, anxious, or on edge,” and “not
being able to stop or control worrying,” on a four-point Likert scale from 0 (not at all) to 3
(nearly every day). Responses were summed and respondent total scores of three or greater were
categorized as having a probable anxiety disorder. A cut-point of three or greater on the GAD-2
has demonstrated a high level of sensitivity (.80) and specificity (.81) for identifying anxiety
disorders (Plummer, Manea, Trepel, & McMillan, 2016).
Difficulties with Emotion Regulation. The Difficulties in Emotion Regulation Scale
(DERS) is a 36-item questionnaire that represents an individuals’ difficulties with emotion
regulation (Appendix A-1). Emotion regulation involves (a) recognition and comprehension of
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emotions, (b) acceptance of emotions, (c) the ability to control spontaneous behaviors and
behave appropriately when experiencing negative emotions and (d) the ability to use proper
emotion regulation strategies to regulate emotional responses. DERS items focus on the
management of negative emotional states (i.e., many items begin with the phrase “When I’m
upset”). Responses to each item are made on a Likert scale from 1 (almost never) to 5 (almost
always). The DERS includes six subscales measuring (a) nonacceptance of emotional responses,
(b) difficulty engaging in goal-directed behavior when distressed, (c) impulse control difficulties
when distressed, (d) lack of awareness of emotions, (e) limited access to strategies for regulation,
and (f) lack of emotional clarity. Additionally, all items can be summed to calculate a total score
(range 36-180) with higher scores representing greater difficulties in emotion regulation. The
DERS has good predictive validity in predicting trait-like emotion dysregulation (Franklin et al.,
2010). The DERS has demonstrated good test-retest reliability over a period of 4 to 8 weeks
(Gratz & Roemer, 2004) and has shown good internal reliability in previous studies of adults
with a chronic health condition (α = .94; Hallion, Steinman, Tolin, & Diefenbach, 2018) and in
the current sample (α = .96).
Data Analysis
Descriptive statistics were used to characterize the sample. Four separate three-step
binary logistic regression models were used to examine the association of DERS with both
measures of short-acting inhaler overuse (i.e., using more than three canisters in the past three
months and self-reported overuse), and emergency department visits and hospitalizations.
Participant medical characteristics (i.e., smoking status and health insurance) were entered in a
first step. Psychiatric variables (i.e., probable depression and probable anxiety) were entered in a
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second step. The main predictor of interest, the DERS, was added in a third step. All analyses
were performed using SPSS 26.0 (IBM Corp, 2016).
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RESULTS
Sample Characteristics
The sample was relatively diverse in terms of demographic variables. See Table 1. More
than half of the sample was female with an average age of 45.09 (SD = 16.43) years. With
respect to race and ethnicity, the sample was approximately half White, nearly a quarter Black or
African American, and 71.6% non-Hispanic. Three quarters of the sample had equivalent to or
more than some college experience and about a third of the sample had an income greater than or
equivalent to $55,000 a year. Approximately half of the sample were current smokers. Most
participants had health insurance and a primary care provider during the prior 12-months. With
regards to short-acting inhaled medication overuse, 38.3% of the sample used more than three
canisters within the past three months and 19.4% of the sample reported that they had used their
inhaler more than prescribed because they felt as if their symptoms were getting worse. In terms
of acute medical care use, 30.7% of the sample visited the emergency department within the past
twelve months and 22.4% of the sample had been admitted to the hospital within the past twelve
months due to their respiratory condition.
Short-Acting Medication Adherence
A binary logistic regression model was used to assess whether greater emotion regulation
difficulty was associated with using more than three canisters in the past three months. Smoking
and health insurance status were added in the first step. See Table 2. Smoking was significantly
associated with using more than three canisters in the past three months (AOR = 6.178, 95%CI
[3.664, 10.419], p < .001), whereas health insurance status was not (AOR = 1.006, 95%CI [.418,
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2.419], p=.990). Probable depression and probable anxiety were added in the second step.
Probable depression was significantly associated with using more than three canisters of shortacting inhalers in the past three months (AOR = 3.536, 95%CI [1.496, 8.357], p = .004), whereas
probably anxiety was not (AOR = 1.407, 95%CI [.604, 3.277], p = .429). Difficulties in emotion
regulation, added in the third step, was significantly associated with greater odds of using more
than three canisters of short-acting inhalers in the past three months above and beyond variables
entered in the previous two steps (AOR = 1.023, 95%CI [1.012, 1.035], p < .001). In the third
step, probable depression became non-significant (AOR = 2.130, 95%CI [.852, 5.323], p = .106).
A binary logistic regression model was used to assess whether greater emotion regulation
difficulty would be associated with self-reported overuse of short-acting inhaled medications.
Smoking and health insurance status were added in the first step. Smoking was significantly
associated with short-acting rescue inhaler overuse (AOR = 4.178, 95%CI [2.587, 6.750], p
<.001), whereas health insurance status was not (AOR = .997, 95%CI [.426, 2.333], p =.995). See
Table 3. Probable depression and probable anxiety were added in the second step. Probable
depression was not significantly associated with self-reported short-acting rescue inhaler overuse
(AOR = 1.911, 95%CI [.855, 4.272], p = .114), and probable anxiety was also not a significant
predictor (AOR = 1.043, 95%CI [.466, 2.334], p = .919). Difficulties in emotion regulation,
added in the third step, was significantly associated with greater odds of self-reported shortacting rescue inhaler overuse, above and beyond variables entered in the previous two steps
(AOR = 1.024, 95%CI [1.014, 1.035], p <.001).
Acute Medical Care
A binary logistic regression model was used to assess whether greater emotion regulation
difficulty would be associated with more emergency department visits. Smoking and health
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insurance status were added in the first step. Smoking was significantly associated with
emergency room visits (AOR = 3.784, 95%CI [2.367, 6.047], p <.001), whereas health insurance
status was not (AOR = 1.304, 95%CI [.589, 2.888], p =.512). See Table 4. Probable depression
and probable anxiety were added in the second step. Probable depression (AOR = 1.913, 95%CI
[.910, 4.023], p = .087) and probable anxiety (AOR = 1.101, 95%CI [.530, 2.289], p = .796) were
not significantly associated with odds of an emergency department visit in the prior 12-months.
Difficulties in emotion regulation, added in the third step, was significantly associated with
greater odds of an emergency department visit in the prior 12-months, above and beyond
variables entered in the previous two steps (AOR = 1.018, 95%CI [1.009, 1.028], p <.001).
A binary logistic regression model was used to assess whether greater emotion regulation
difficulty would be associated with more hospitalizations. Smoking and health insurance status
were added in the first step. Smoking was significantly associated with greater risk of a
hospitalization in the prior 12-months (AOR = 3.991, 95%CI [2.328, 6.841], p <.001), whereas
health insurance status was not (AOR = 1.698, 95%CI [.666, 4.327], p =.267). See Table 5.
Probable depression and probable anxiety were added in the second step. Probable depression
(AOR = 1.639, 95%CI [.761, 3.532], p = .207) and anxiety (AOR = 1.886, 95%CI [.897, 3.967], p
= .094) were not significantly associated with hospitalizations. Difficulties in emotion regulation,
added in the third step, was significantly associated with greater odds of any hospitalizations in
the prior 12-months (AOR = 1.017, 95%CI [1.007, 1.028], p = .001), above and beyond the
previous two steps.
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Table 1
Sociodemographic and Clinical Sample Characteristics (n = 401).
Variable

n (%) or Mean (SD)

Age
45.09 ± 16.43
Female
57.9
Race
White
49.6
Black
27.7
Asian
12.5
American Indian
4.2
Native Hawaiian
2.0
Multiracial
9.2
Ethnicity (Latino)
28.4
Education
< High school
3.5
High school
21.2
≥ Some college
75.3
Income
< 15,000
15.7
15,000 to 30,000
21.4
30,000 to 55,000
28.7
≥ 55,000
34.2
Current smoker
52.6
Health insurance
91.3
Primary care provider
94.0
Probable depression (PHQ-2 ≥ 3)
12.5
Probable anxiety (GAD-2 ≥ 3)
13.2
DERS
83.64 ± 28.43
Short-acting inhaled medication use
>3 canisters in 3 months
38.3
Self-reported overuse
19.4
Emergency Dept. visits
30.7
Hospitalizations
22.4
PHQ-2 = Patient Health Questionnaire-2; GAD-2 = Generalized
Anxiety Disorder-2; DERS = Difficulties in Emotion Regulation
Scale
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Table 2
Binary Logistic Regression Examining the Association between Emotion
Regulation (DERS) and > 3 Canisters of Short-Acting Inhaled
Medications (n = 326).
AOR

SE

p

95% CI

Current Smoker

6.178

.267

<.001

3.664

10.419

Health Insurance

1.006

.448

.990

.418

2.419

Current Smoker

6.039

.275

<.001

3.526

10.343

Health Insurance

1.046

.460

.922

.425

2.577

Probable Depression

3.536

.439

.004

1.496

8.357

Probable Anxiety

1.407

.431

.429

.604

3.277

Current Smoker

5.218

.282

<.001

3.003

9.067

Health Insurance

1.079

.467

.870

.432

2.696

Probable Depression

2.130

.467

.106

.852

5.323

Probable Anxiety

.855

.461

.734

.346

2.111

DERS

1.023

.006

<.001

1.012

1.035

Step 1

Step 2

Step 3

AOR = Adjusted Odds Ratio; DERS = Difficulties in Emotion Regulation
Scale
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Table 3
Binary Logistic Regression Examining the Association between Emotion
Regulation (DERS) and Self-Reported Overuse of Short-Acting Inhaled
Medications (n = 326).
AOR

SE

p

95% CI

Current Smoker

4.178

.245

<.001

2.587

6.750

Health Insurance

.997

.433

.995

.426

2.333

Current Smoker

4.029

.246

<.001

2.485

6.531

Health Insurance

1.027

.436

.952

.437

2.412

Probable Depression

1.911

.410

.114

.855

4.272

Probable Anxiety

1.043

.411

.919

.466

2.334

Current Smoker

3.441

.256

<.001

2.085

5.679

Health Insurance

1.072

.444

.876

.448

2.561

Probable Depression

1.096

.440

.834

.463

2.596

Probable Anxiety

.626

.439

.287

.265

1.482

DERS

1.024

.005

<.001

1.014

1.035

Step 1

Step 2

Step 3

AOR= Adjusted Odds Ratio; DERS = Difficulties in Emotion Regulation
Scale
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Table 4
Binary Logistic Regression Examining the Association between Emotion
Regulation (DERS) and Emergency Department Visits during the past 12
months (n =401).
AOR

SE

p

95% CI

Current Smoker

3.784

.239

<.001

2.367

6.047

Health Insurance

1.304

.406

.512

.589

2.888

Current Smoker

3.606

.241

<.001

2.247

5.789

Health Insurance

1.302

.408

.518

.585

2.897

Probable Depression

1.913

.379

.087

.910

4.023

Probable Anxiety

1.101

.373

.796

.530

2.289

Current Smoker

3.139

.247

<.001

1.934

5.093

Health Insurance

1.272

.411

.558

.568

2.849

Probable Depression

1.229

.400

.606

.561

2.691

Probable Anxiety

.782

.389

.526

.365

1.674

DERS

1.018

.005

<.001

1.009

1.028

Step 1

Step 2

Step 3

AOR = Adjusted Odds Ratio; DERS = Difficulties in Emotion Regulation
Scale
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Table 5
Binary Logistic Regression Examining the Association between Emotion
Regulation (DERS) and Hospitalizations during the past 12 months (n
=401).
AOR

SE

p

95% CI

Current Smoker

3.991

.275

<.001

2.328

6.841

Health Insurance

1.698

.477

.267

.666

4.327

Current Smoker

3.688

.278

<.001

2.137

6.363

Health Insurance

1.657

.485

.298

.640

4.289

Probable Depression

1.639

.392

.207

.761

3.532

Probable Anxiety

1.886

.379

.094

.897

3.967

Current Smoker

3.181

.284

<.001

1.823

5.549

Health Insurance

1.602

.488

.334

.616

4.166

Probable Depression

1.079

.412

.854

.481

2.421

Probable Anxiety

1.387

.393

.405

.642

2.997

DERS

1.017

.005

.001

1.007

1.028

Step 1

Step 2

Step 3

AOR = Adjusted Odds Ratio; DERS = Difficulties in Emotion Regulation
Scale
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DISCUSSION
This study is among the first to examine the links between emotion regulation,
medication adherence, and utilization of acute medical care among adults with asthma. As
hypothesized, difficulties regulating emotion were associated with an increased probability of
overusing short-acting inhaled medications and with having one or more emergency room visits
or hospitalizations during the prior 12-months. These relationships remained significant even
when controlling for patient characteristics (i.e., smoking and health insurance status), and
current mental health symptoms (i.e., probable anxiety and depression).
Overuse of Short-Acting Inhaled Medications
Results from the present study suggest that difficulties with emotion regulation play an
important role in overuse of short-acting inhaled medications, above and beyond anxiety and
depression. A strength of this study is that overuse of short-acting inhaled medications was
measured using two separate approaches. First, we assessed respondents self-reported overuse in
terms of short-acting inhaled medications using a validated threshold (i.e., use of more than three
canisters in the prior three months) associated with worse asthma related outcomes (e.g., greater
use of acute medical care, greater asthma symptom burden; Gerald et al., 2015; Silver et al.,
2010). Second, we assessed respondents self-reported overuse in terms of their non-adherence to
their healthcare provider’s recommendations (e.g., using medications more than prescribed
because of asthma symptoms). Notably, our results showed that difficulties in emotion regulation
was strongly associated with both measures of self-reported inhaled medication overuse.
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Together, these results suggest that adults with asthma who experience greater difficulties
regulating their emotions are more likely to overuse short-acting inhaled medications.
Prior studies have found that symptoms of anxiety and depression are associated with
medication overuse among patients with asthma (Gerald & Moreno, 2016; Strek, 2006;
Thomson, 2015). Together these findings suggest that difficulties in emotion regulation, rather
than symptoms of anxiety and depression, could contribute to overuse of short-acting inhaled
medications among adults with asthma. Specifically, difficulties in emotion regulation may
represent an underlying vulnerability among adults with asthma associated with both increased
risk of comorbid anxiety and depression as well as with a propensity for overusing short-acting
inhaled medications. Indeed, prior studies have consistently identified difficulties with emotion
regulation as a stable trait-like vulnerability associated with the development of depression and
anxiety (Amstadter, 2008). Patients with anxiety who have emotion regulation difficulties are
more likely to engage in compensatory behaviors (e.g., safety behaviors) to reduce aversive
emotions (Cisler, Olatunji, Feldner, & Forsyth, 2010). Adults with asthma who have difficulties
regulating aversive emotions may use short-acting inhaled medications as a similar
compensatory strategy.
Our findings are consistent with prior studies which have shown that strong emotions
may trigger asthma symptoms and that negative emotions may worsen asthma symptoms
(Lehrer, Isenberg, & Hochron, 1993; Ritz, 2004; Ritz & Kullowatz, 2005). For example,
previous studies have demonstrated that greater airway inflammation and bronchial constriction
in response to experimental induction of strong emotions and that responsiveness to emotion
induced airway were linked with greater patient reported frequency of psychological triggers for
asthma symptoms (Ritz et al., 2010). Furthermore, previous research has linked changes in lung

20

functioning and emotional states (Ritz, 2012). Other studies provide evidence suggesting that
negative emotional states are associated with a decrease in lung functioning in asthma patients
(e.g., FEV1; Kullowatz et al., 2008; Ritz, 2004; Ritz & Kullowatz, 2005; Ritz & Steptoe, 2000).
In addition, studies suggest that different emotions affect breathing patterns in unique ways (i.e.,
anxious and negative emotions correlate with quick and shallow breathing patterns while happy
and positive emotions are associated with slow and full breaths; Philippot, Chapelle, & Blairy,
2002). It is possible that, among adults with asthma, difficulties regulating emotions may
precipitate greater asthma symptoms, thus resulting in greater attempts to manage these
symptoms using short-acting inhaled medications.
Use of Acute Medical Care
Results from the present study also suggest that difficulties with emotion regulation play
a major role in greater use of acute medical care (e.g., emergency department visits and
hospitalizations) in the prior 12 months. Prior studies have found that adults with asthma and
depressive symptoms have higher rates of hospitalizations (Kullowatz et al., 2007). Collectively,
these findings suggest that anxiety, depression, and difficulties with emotion regulation are
linked with more emergency department visits and hospitalizations among adults with asthma.
Moreover, at least one prior study found that adults with asthma have higher rates of depressive
symptoms compared to adults without asthma and that depressive symptoms in adults with
asthma are associated with increased risk of hospitalizations and poor health outcomes (Eisner,
Katz, Lactao, & Iribarren, 2005; Kewalramani, Bollinger, & Postolache, 2008). The present
study extends these findings by demonstrating that difficulties with emotion regulation are
significantly associated with acute medical service use, above and beyond variance associated
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with depression and anxiety. The present findings suggest that emotion regulation may be an
important clinical factor in the treatment and management of asthma symptoms.
Limitations
Findings from this study are qualified by two important limitations. First, overuse of
short-acting inhaled medications and acute medical service use were measured using
respondents’ self-report which is subject to recall errors. Future studies should use electronic
medical records (e.g., pharmacy records of canister refills, emergency room visits, in-patient
hospitalizations) to objectively assess overuse of short-acting inhaled medications and use of
acute medical care. Additionally, future studies could use Metered Dose Inhalers to more
accurately measure individuals daily frequency of inhaler use (Nowacki & Brisson, 1985). Such
approaches would provide more precise estimates of the relationship between difficulties
regulating emotions and overuse of short-acting inhaled medications. However, these strategies
require time and expense. Second, we were not able to confirm the medical diagnosis of asthma.
Third, this study used a cross-sectional design which undermines our ability to determine the
causal relationship between difficulties in emotion regulation and the study outcomes.
Clinical Implications
Our results suggest that difficulties regulating emotion may represent an important
vulnerability among adults with asthma. If confirmed by additional studies, our results suggest
that certain adults with asthma may benefit from screening for emotion regulation by health care
providers (e.g., pharmacists, nurses, physicians) to identify patients at risk for overuse of shortacting inhaled medications or acute service use. Such screening could help reduce risks
associated with overusing rescue inhalers (e.g., more severe asthma symptoms, more frequent
symptom exacerbations characterized by an increase in dyspnea and decrease in pulmonary
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function, and greater risk of developing metabolic syndromes). Further, screening could help
reduce unnecessary and costly emergency department visits and hospitalizations. Providing
asthma patients with knowledge and skills to regulate emotions and control asthma symptoms
could also help limit costly acute medical care use in adults with asthma.
Future research could examine whether patients with asthma may benefit from
interventions to reduce overuse of short-acting inhaled medications and utilization of acute
medical care. Interventions targeting overuse of inhaled medications and acute service use which
focus on treatment of anxiety and depression may not be as effective as treatments targeting
emotion regulation directly. For example, emotion regulation skills from existing empirically
supported interventions such as Dialectic Behavioral Therapy (DBT) could be used to directly
target difficulties with emotion regulation. DBT is a type of cognitive behavioral therapy that
was initially developed to treat individuals with borderline personality disorder by providing
them the skills necessary to improve their ability to modulate strong negative emotions (Linehan,
2014). These skills include mindfulness skills, interpersonal effectiveness skills, emotion
regulation skills, distress tolerance skills and behavioral strategies (Linehan, 2014). The emotion
regulation skills section of the DBT treatment manual recommends strategies to help you
manage your emotions and increase your emotional resilience (Linehan, 2014). Future studies
could assess whether such skill-based interventions could be used to improve emotion regulation
in adults with asthma and thus improve medication adherence of short-acting inhaled
medications and reduce utilization of costly acute medical care.
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APPENDIX A-1
Difficulties in Emotion Regulation Scale (DERS-36)
Directions: Please indicate how often the following statements apply to you by selecting the
appropriate number from the scale above.
Response options: 1 - Almost never (0-10%), 2 – Sometimes (11-35%), 3 - About half the time
(36-65%), 4 - Most of the time (66-90%), 5 - Almost always (91-100%)
1. I am clear about my feelings.
2. I pay attention to how I feel.
3. I experience my emotions as overwhelming and out of control.
4. I have no idea how I am feeling.
5. I have difficulty making sense out of my feelings.
6. I am attentive to my feelings.
7. I know exactly how I am feeling.
8. I care about what I am feeling.
9. I am confused about how I feel.
10. When I’m upset, I acknowledge my emotions.
11. When I’m upset, I become angry with myself for feeling that way.
12. When I’m upset, I become embarrassed for feeling that way.
13. When I’m upset, I have difficulty getting work done.
14. When I’m upset, I become out of control.
15. When I’m upset, I believe that I will remain that way for a long time.
16. When I’m upset, I believe that I will end up feeling very depressed.
17. When I’m upset, I believe that my feelings are valid and important.
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18. When I’m upset, I have difficulty focusing on other things.
19. When I’m upset, I feel out of control.
20. When I’m upset, I can still get things done.
21. When I’m upset, I feel ashamed at myself for feeling that way.
22. When I’m upset, I know that I can find a way to eventually that way.
23. When I’m upset, I feel like I am weak.
24. When I’m upset, I feel like I can remain in control of my behaviors.
25. When I’m upset, I feel guilty for feeling that way.
26. When I’m upset, I have difficulty concentrating.
27. When I’m upset, I have difficulty controlling my behaviors.
28. When I’m upset, I believe there is nothing I can do to make myself feel better.
29. When I’m upset, I become irritated at myself for feeling that way.
30. When I’m upset, I start to feel very bad about myself.
31. When I’m upset, I believe that wallowing in it is all I can do.
32. When I’m upset, I lose control over my behavior.
33. When I’m upset, I have difficulty thinking about anything else.
34. When I’m upset, I take time to figure out what I’m really feeling.
35. When I’m upset, it takes me a long time to feel better.
36. When I’m upset, my emotions feel overwhelming.
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